Saltar al contenido
Merck

SAB4504605

Anti-phospho-AXL (pTyr698) antibody produced in rabbit

affinity isolated antibody

Sinónimos:

Anti-ARK, Anti-JTK11, Anti-Tyro7, Anti-UFO

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Cambiar Vistas

Acerca de este artículo

NACRES:
NA.41
UNSPSC Code:
12352203
Conjugate:
unconjugated
Clone:
polyclonal
Application:
ELISA, IHC, WB
Citations:
9
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle


biological source

rabbit

Quality Level

conjugate

unconjugated

antibody form

affinity isolated antibody

antibody product type

primary antibodies

clone

polyclonal

form

buffered aqueous solution

mol wt

antigen 97 kDa

species reactivity

human, mouse, rat

concentration

~1 mg/mL

technique(s)

ELISA: 1:20000, immunohistochemistry: 1:50-1:100, western blot: 1:500-1:1000

NCBI accession no.

UniProt accession no.

shipped in

wet ice

storage temp.

−20°C

target post-translational modification

phosphorylation (pTyr698)

Gene Information

human ... AXL(558)

General description

AXL (receptor tyrosine kinase) is also termed as Ark, UFO or Tyro7. This gene is overexpressed in pancreatic cancer tissues. AXL belongs to the receptor tyrosine kinase family. It is obtained as a transforming gene from human leukemia cells. AXL is mapped to human chromosome 19q13.

Immunogen

The antiserum was produced against synthesized peptide derived from human AXL around the phosphorylation site of Tyr691.

Immunogen Range: 657-706

Biochem/physiol Actions

AXL (receptor tyrosine kinase) controls innate immune responses. It participates in cellular transformation and tumor progression. Overexpression of AXL is characterized with higher liability for lymphatic metastases.

Features and Benefits

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

Physical form

Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.


Still not finding the right product?

Pruebe nuestra Herramienta de selección de productos para limitar sus opciones


Clase de almacenamiento

10 - Combustible liquids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable



Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos



Victoria H Cruz et al.
JCI insight, 5 (2019-04-03)
Pancreatic ductal adenocarcinoma (PDA) is characterized by an activating mutation in KRAS. Direct inhibition of KRAS through pharmacological means remains a challenge; however, targeting key KRAS effectors has therapeutic potential. We investigated the contribution of TANK-binding kinase 1 (TBK1), a
Yanting Duan et al.
Oncology letters, 17(6), 5784-5792 (2019-06-13)
AXL receptor tyrosine kinase ligand (AXL), a tyrosine kinase receptor that is commonly overexpressed in numerous types of cancer, significantly promotes drug resistance and metastasis in tumor cells. Inhibition of the AXL/growth arrest-specific 6 (Gas6) signaling pathway is emerging as
The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target.
Koorstra JBM, et al.
Cancer Biology & Therapy, 8(7), 618-626 (2009)